Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1995 Nov;116(5):2482–2486. doi: 10.1111/j.1476-5381.1995.tb15099.x

Roles of endothelin receptors in the regional and systemic vascular responses to ET-1 in the anaesthetized ganglion-blocked rat: use of selective antagonists.

G H Allcock 1, T D Warner 1, J R Vane 1
PMCID: PMC1909069  PMID: 8581288

Abstract

1. Endothelin-1 (ET-1) produces vasoconstriction, via activation of ETA and ETB receptors on vascular smooth muscle, and vasodilatation via ETB receptors on endothelial cells. Here we have used the ETA receptor-selective antagonist, BQ-123, the ETB receptor-selective antagonist, BQ-788 and the ETA/ETB receptor non-selective antagonist, PD 145065, to study the role of these receptors in mediating the haemodynamic changes induced by an infusion of ET-1 to the anesthetized ganglion-blocked rat. 2. Infusion of ET-1 (10 pmol kg-1 min-1) increased the mean arterial pressure (MAP) by 57.5 +/- 5.1 mmHg over 70 min. This pressor response was reduced by about 50% by coinfusion of BQ-123 (10 mmol kg-1 min-1), but was unaffected by either BQ-788 (10 nmol kg-1 min-1) or PD 145065 (10 nmol kg-1 min-1). 3. After infusion of ET-1 for 70 min the cardiac output had fallen from 102.6 +/- 11.3 to 55.7 +/- 7.6 ml min-1 and the total peripheral resistance had increased from 3.24 +/- 0.6 to 10.0 +/- 0.8 mmHg ml-1 min-1 (per 100g body weight). BQ-123 decreased the magnitudes of these changes whereas BQ-788 potentiated them. PD 145065 was without effect. 4. ET-1 increased the vascular resistances of all the organs studied except the brain and stomach. These changes were attenuated by BQ-123 in the kidneys, skin, adrenal glands and caecum and potentiated by BQ-788 in the kidneys, small intestine, large intestine and mesentery. PD 145065 had little effect on the individual tissues. 5. Thus, BQ-123, a selective ETA receptor antagonist, inhibits the pressor and vascular constrictor effects of ET-1 more actively than PD 145065. As BQ-788 potentiates some of the vasoconstrictor effects of ET-1 and increases the effects of ET-1 on total peripheral resistance, the predominant role of ETB receptors in the rat circulation is to limit the pressor effects of ET-1.

Full text

PDF
2482

Images in this article

2484Figure 2
on p.2484

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Beyer M. E., Nerz S., Krämer B. K., Hoffmeister H. M. Hemodynamic and inotropic effects of endothelin-1 in vivo. Basic Res Cardiol. 1994 Jan-Feb;89(1):39–49. doi: 10.1007/BF00788676. [DOI] [PubMed] [Google Scholar]
  2. Clozel M., Breu V., Burri K., Cassal J. M., Fischli W., Gray G. A., Hirth G., Löffler B. M., Müller M., Neidhart W. Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist. Nature. 1993 Oct 21;365(6448):759–761. doi: 10.1038/365759a0. [DOI] [PubMed] [Google Scholar]
  3. Clozel M., Gray G. A., Breu V., Löffler B. M., Osterwalder R. The endothelin ETB receptor mediates both vasodilation and vasoconstriction in vivo. Biochem Biophys Res Commun. 1992 Jul 31;186(2):867–873. doi: 10.1016/0006-291x(92)90826-7. [DOI] [PubMed] [Google Scholar]
  4. Cristol J. P., Warner T. D., Thiemermann C., Vane J. R. Mediation via different receptors of the vasoconstrictor effects of endothelins and sarafotoxins in the systemic circulation and renal vasculature of the anaesthetized rat. Br J Pharmacol. 1993 Mar;108(3):776–779. doi: 10.1111/j.1476-5381.1993.tb12877.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Fukuroda T., Fujikawa T., Ozaki S., Ishikawa K., Yano M., Nishikibe M. Clearance of circulating endothelin-1 by ETB receptors in rats. Biochem Biophys Res Commun. 1994 Mar 30;199(3):1461–1465. doi: 10.1006/bbrc.1994.1395. [DOI] [PubMed] [Google Scholar]
  6. Fukuroda T., Ozaki S., Ihara M., Ishikawa K., Yano M., Nishikibe M. Synergistic inhibition by BQ-123 and BQ-788 of endothelin-1-induced contractions of the rabbit pulmonary artery. Br J Pharmacol. 1994 Oct;113(2):336–338. doi: 10.1111/j.1476-5381.1994.tb16901.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Gardiner S. M., Kemp P. A., March J. E., Bennett T., Davenport A. P., Edvinsson L. Effects of an ET1-receptor antagonist, FR139317, on regional haemodynamic responses to endothelin-1 and [Ala11,15]Ac-endothelin-1 (6-21) in conscious rats. Br J Pharmacol. 1994 Jun;112(2):477–486. doi: 10.1111/j.1476-5381.1994.tb13098.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Gardiner S. M., Kemp P. A., March J. E., Bennett T. Effects of bosentan (Ro 47-0203), an ETA-, ETB-receptor antagonist, on regional haemodynamic responses to endothelins in conscious rats. Br J Pharmacol. 1994 Jul;112(3):823–830. doi: 10.1111/j.1476-5381.1994.tb13153.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Haynes W. G., Webb D. J. Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet. 1994 Sep 24;344(8926):852–854. doi: 10.1016/s0140-6736(94)92827-4. [DOI] [PubMed] [Google Scholar]
  10. Ihara M., Noguchi K., Saeki T., Fukuroda T., Tsuchida S., Kimura S., Fukami T., Ishikawa K., Nishikibe M., Yano M. Biological profiles of highly potent novel endothelin antagonists selective for the ETA receptor. Life Sci. 1992;50(4):247–255. doi: 10.1016/0024-3205(92)90331-i. [DOI] [PubMed] [Google Scholar]
  11. Ishikawa K., Ihara M., Noguchi K., Mase T., Mino N., Saeki T., Fukuroda T., Fukami T., Ozaki S., Nagase T. Biochemical and pharmacological profile of a potent and selective endothelin B-receptor antagonist, BQ-788. Proc Natl Acad Sci U S A. 1994 May 24;91(11):4892–4896. doi: 10.1073/pnas.91.11.4892. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. LaDouceur D. M., Flynn M. A., Keiser J. A., Reynolds E., Haleen S. J. ETA and ETB receptors coexist on rabbit pulmonary artery vascular smooth muscle mediating contraction. Biochem Biophys Res Commun. 1993 Oct 15;196(1):209–215. doi: 10.1006/bbrc.1993.2236. [DOI] [PubMed] [Google Scholar]
  13. Lawrence E., Brain S. D. Effect of BQ-123 and Ro 47-0203 (bosentan) on endothelin-induced vasoconstriction in the rat skin. Eur J Pharmacol. 1994 Jul 21;260(1):103–106. doi: 10.1016/0014-2999(94)90017-5. [DOI] [PubMed] [Google Scholar]
  14. Le Monnier de Gouville A. C., Mondot S., Lippton H., Hyman A., Cavero I. Hemodynamic and pharmacological evaluation of the vasodilator and vasoconstrictor effects of endothelin-1 in rats. J Pharmacol Exp Ther. 1990 Jan;252(1):300–311. [PubMed] [Google Scholar]
  15. Lopez-Belmonte J., Whittle B. J. The involvement of endothelial dysfunction, nitric oxide and prostanoids in the rat gastric microcirculatory responses to endothelin-1. Br J Pharmacol. 1994 May;112(1):267–271. doi: 10.1111/j.1476-5381.1994.tb13062.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Lopez-Belmonte J., Whittle B. J. The paradoxical vascular interactions between endothelin-1 and calcitonin gene-related peptide in the rat gastric mucosal microcirculation. Br J Pharmacol. 1993 Sep;110(1):496–500. doi: 10.1111/j.1476-5381.1993.tb13838.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. McDevitt D. G., Nies A. S. Simultaneous measurement of cardiac output and its distribution with microspheres in the rat. Cardiovasc Res. 1976 Jul;10(4):494–498. doi: 10.1093/cvr/10.4.494. [DOI] [PubMed] [Google Scholar]
  18. McMurdo L., Corder R., Thiemermann C., Vane J. R. Incomplete inhibition of the pressor effects of endothelin-1 and related peptides in the anaesthetized rat with BQ-123 provides evidence for more than one vasoconstrictor receptor. Br J Pharmacol. 1993 Feb;108(2):557–561. doi: 10.1111/j.1476-5381.1993.tb12840.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Nishikibe M., Tsuchida S., Okada M., Fukuroda T., Shimamoto K., Yano M., Ishikawa K., Ikemoto F. Antihypertensive effect of a newly synthesized endothelin antagonist, BQ-123, in a genetic hypertensive model. Life Sci. 1993;52(8):717–724. doi: 10.1016/0024-3205(93)90233-s. [DOI] [PubMed] [Google Scholar]
  20. Ohlstein E. H., Nambi P., Douglas S. A., Edwards R. M., Gellai M., Lago A., Leber J. D., Cousins R. D., Gao A., Frazee J. S. SB 209670, a rationally designed potent nonpeptide endothelin receptor antagonist. Proc Natl Acad Sci U S A. 1994 Aug 16;91(17):8052–8056. doi: 10.1073/pnas.91.17.8052. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Ohlstein E. H., Vickery L., Sauermelch C., Willette R. N. Vasodilation induced by endothelin: role of EDRF and prostanoids in rat hindquarters. Am J Physiol. 1990 Dec;259(6 Pt 2):H1835–H1841. doi: 10.1152/ajpheart.1990.259.6.H1835. [DOI] [PubMed] [Google Scholar]
  22. Rubanyi G. M., Polokoff M. A. Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol Rev. 1994 Sep;46(3):325–415. [PubMed] [Google Scholar]
  23. Shetty S. S., Okada T., Webb R. L., DelGrande D., Lappe R. W. Functionally distinct endothelin B receptors in vascular endothelium and smooth muscle. Biochem Biophys Res Commun. 1993 Mar 15;191(2):459–464. doi: 10.1006/bbrc.1993.1240. [DOI] [PubMed] [Google Scholar]
  24. Sumner M. J., Cannon T. R., Mundin J. W., White D. G., Watts I. S. Endothelin ETA and ETB receptors mediate vascular smooth muscle contraction. Br J Pharmacol. 1992 Nov;107(3):858–860. doi: 10.1111/j.1476-5381.1992.tb14537.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Thomas G. R., Thiemermann C., Walder C., Vane J. R. The effects of endothelium-dependent vasodilators on cardiac output and their distribution in the anaesthetized rat: a comparison with sodium nitroprusside. Br J Pharmacol. 1988 Nov;95(3):986–992. doi: 10.1111/j.1476-5381.1988.tb11729.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Wallace J. L., Keenan C. M., MacNaughton W. K., McKnight G. W. Comparison of the effects of endothelin-1 and endothelin-3 on the rat stomach. Eur J Pharmacol. 1989 Aug 11;167(1):41–47. doi: 10.1016/0014-2999(89)90745-0. [DOI] [PubMed] [Google Scholar]
  27. Warner T. D., Allcock G. H., Corder R., Vane J. R. Use of the endothelin antagonists BQ-123 and PD 142893 to reveal three endothelin receptors mediating smooth muscle contraction and the release of EDRF. Br J Pharmacol. 1993 Oct;110(2):777–782. doi: 10.1111/j.1476-5381.1993.tb13879.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Warner T. D., Allcock G. H., Vane J. R. Reversal of established responses to endothelin-1 in vivo and in vitro by the endothelin receptor antagonists, BQ-123 and PD 145065. Br J Pharmacol. 1994 May;112(1):207–213. doi: 10.1111/j.1476-5381.1994.tb13053.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Warner T. D., Battistini B., Allcock G. H., Vane J. R. Endothelin ETA and ETB receptors mediate vasoconstriction and prostanoid release in the isolated kidney of the rat. Eur J Pharmacol. 1993 Dec 21;250(3):447–453. doi: 10.1016/0014-2999(93)90032-d. [DOI] [PubMed] [Google Scholar]
  30. Wellings R. P., Corder R., Warner T. D., Cristol J. P., Thiemermann C., Vane J. R. Evidence from receptor antagonists of an important role for ETB receptor-mediated vasoconstrictor effects of endothelin-1 in the rat kidney. Br J Pharmacol. 1994 Feb;111(2):515–520. doi: 10.1111/j.1476-5381.1994.tb14767.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Yanagisawa M., Kurihara H., Kimura S., Tomobe Y., Kobayashi M., Mitsui Y., Yazaki Y., Goto K., Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988 Mar 31;332(6163):411–415. doi: 10.1038/332411a0. [DOI] [PubMed] [Google Scholar]
  32. de Nucci G., Thomas R., D'Orleans-Juste P., Antunes E., Walder C., Warner T. D., Vane J. R. Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc Natl Acad Sci U S A. 1988 Dec;85(24):9797–9800. doi: 10.1073/pnas.85.24.9797. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES